297 related articles for article (PubMed ID: 34930786)
21.
Stagni C; Zamuner C; Elefanti L; Zanin T; Bianco PD; Sommariva A; Fabozzi A; Pigozzo J; Mocellin S; Montesco MC; Chiarion-Sileni V; De Nicolo A; Menin C
Mol Cancer Ther; 2018 Jun; 17(6):1332-1340. PubMed ID: 29626128
[TBL] [Abstract][Full Text] [Related]
22.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
23. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
24. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
[TBL] [Abstract][Full Text] [Related]
25. Intermittent treatment of BRAF
Kavran AJ; Stuart SA; Hayashi KR; Basken JM; Brandhuber BJ; Ahn NG
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2113535119. PubMed ID: 35290123
[TBL] [Abstract][Full Text] [Related]
26. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
27. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
28. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A
PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965
[TBL] [Abstract][Full Text] [Related]
29. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
30. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
31. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
32. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
33. BRAF Inhibitors in Melanoma Management: When Friends Become Foes.
Chhabra G; Ahmad N
J Invest Dermatol; 2022 May; 142(5):1256-1259. PubMed ID: 34872726
[TBL] [Abstract][Full Text] [Related]
34. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib.
Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G
Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143
[TBL] [Abstract][Full Text] [Related]
35. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.
Smith MP; Brunton H; Rowling EJ; Ferguson J; Arozarena I; Miskolczi Z; Lee JL; Girotti MR; Marais R; Levesque MP; Dummer R; Frederick DT; Flaherty KT; Cooper ZA; Wargo JA; Wellbrock C
Cancer Cell; 2016 Mar; 29(3):270-284. PubMed ID: 26977879
[TBL] [Abstract][Full Text] [Related]
36. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
[TBL] [Abstract][Full Text] [Related]
37. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
[TBL] [Abstract][Full Text] [Related]
38. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
39. Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.
Gao MZ; Wang HB; Chen XL; Cao WT; Fu L; Li Y; Quan HT; Xie CY; Lou LG
Acta Pharmacol Sin; 2019 Feb; 40(2):268-278. PubMed ID: 29777202
[TBL] [Abstract][Full Text] [Related]
40. Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
Szász I; Koroknai V; Kiss T; Vízkeleti L; Ádány R; Balázs M
Melanoma Res; 2019 Aug; 29(4):390-400. PubMed ID: 30741840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]